Tetrandrine enhances anti-PD-1 immunotherapeutic efficacy for hepatocellular carcinoma by activating STING/TBK1/IRF3 pathway - Top-Institutions - MDSpire

Tetrandrine enhances anti-PD-1 immunotherapeutic efficacy for hepatocellular carcinoma by activating STING/TBK1/IRF3 pathway

  • By

  • Biao Zheng

  • Guojun Yao

  • Yuli Pang

  • Jielong Luo

  • Zhiyong Yang

  • Fengmin Xiu

  • Chaohui Zhen

  • Rui Liang

  • June 9, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    The University of Texas MD Anderson Cancer Center
    The University of Texas MD Anderson Cancer Center

    Houston, Texas

    Key Differentiators

    • Oncology

  • #2

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, New York

    Key Differentiators

    • Oncology

  • #3

    University of California, San Francisco
    University of California, San Francisco

    San Francisco, California

    Key Differentiators

    • Oncology

  • #4

    Institut Gustave Roussy
    Institut Gustave Roussy

    Villejuif, France

    Key Differentiators

    • Oncology

  • #5

    National Cancer Institute Center for Cancer Research
    National Cancer Institute Center for Cancer Research

    Bethesda, Maryland

    Key Differentiators

    • Oncology

Original Source(s)

Tetrandrine enhances anti-PD-1 immunotherapeutic efficacy for hepatocellular carcinoma by activating STING/TBK1/IRF3 pathway

  • by Biao Zheng, Guojun Yao, Yuli Pang, Jielong Luo, Zhiyong Yang, Fengmin Xiu, Chaohui Zhen, Rui Liang

  • June 9, 2026

Related Content

First-line serplulimab plus chemotherapy versus chemotherapy alone in small-cell lung cancer patients with brain metastases: a multicenter, prospective cohort study

This Week’s Biopharma News: Big Moves in Bispecifics

Akeso’s PD-1/VEGF bispecific beats PD-1 plus chemo in lung cancer, Amgen wins EC approval for its DLL3-targeted T-cell engager, and Aragen scales Renaissance’s Fast Track anti-GD2 antibody

  • June 9, 2026

  • 5 min
Association between tumor genomic mutations and the risk of PD-1 inhibitor-induced hypophysitis: a retrospective cohort study